Tumor biomarkers for diagnosis, prognosis and targeted therapy

• Published in: Signal transduction and targeted therapy 2024-05, Vol.9 (1), p.132-132, Article 132
• Main Authors: Zhou, Yue, Tao, Lei, Qiu, Jiahao, Xu, Jing, Yang, Xinyu, Zhang, Yu, Tian, Xinyu, Guan, Xinqi, Cen, Xiaobo, Zhao, Yinglan
• Format: Article
• Language: English
• Subjects: 631/67/1059; 631/67/1857; Biomarkers; Biomarkers, Tumor - genetics; Cancer; Cancer Research; Cell Biology; Classification; Diagnosis; Disease management; Humans; Internal Medicine; Medicine; Medicine & Public Health; Molecular Targeted Therapy; Neoplasms - diagnosis; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - metabolism; Neoplasms - therapy; Oncology; Pathology; Precision Medicine; Prognosis; Review; Review Article; Tumorigenesis; Tumors
• ISSN: 2059-3635; 2095-9907; 2059-3635
• DOI: 10.1038/s41392-024-01823-2

Tumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecular biology technologies developed for the detection of tumor biomarkers. Herein, we summarize the discovery and development of tumor biomarkers, including the history of tumor biomarkers, the conventional and innovative technologies used for biomarker discovery and detection, the classification of tumor biomarkers based on tissue origins, and the application of tumor biomarkers in clinical cancer management. In particular, we highlight the recent advancements in biomarker-based anticancer-targeted therapies which are emerging as breakthroughs and promising cancer therapeutic strategies. We also discuss limitations and challenges that need to be addressed and provide insights and perspectives to turn challenges into opportunities in this field. Collectively, the discovery and application of multiple tumor biomarkers emphasized in this review may provide guidance on improved precision medicine, broaden horizons in future research directions, and expedite the clinical classification of cancer patients according to their molecular biomarkers rather than organs of origin.